{"items": "31", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/24/10/41608586/coya-therapeutics-high-dose-interleukin-2-misses-the-mark-in-mid-stage-alzheimers-study", "time_published": "20241029T183652", "authors": ["Vandana Singh"], "summary": "On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease. The data was shared at the Clinical Trials on Alzheimer's Disease Conference ( CTAD24 ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/29/pharma-lab-worker-ai.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.031041, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Biohaven  ( NYSE:BHVN ) , ARM Holdings  ( NASDAQ:ARM ) ", "url": "https://www.benzinga.com/news/24/09/40878542/this-yelp-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-monday", "time_published": "20240916T132734", "authors": ["Avi Kapoor"], "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Benchmark analyst Cody Acree initiated coverage on Arm Holdings plc ARM with a Hold rating.", "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16085332/image-121-1024x588.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.305664, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BHVN", "relevance_score": "0.375251", "ticker_sentiment_score": "0.301824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "YELP", "relevance_score": "0.485711", "ticker_sentiment_score": "0.344258", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COYA", "relevance_score": "0.375251", "ticker_sentiment_score": "0.134687", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARM", "relevance_score": "0.375251", "ticker_sentiment_score": "0.360009", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMUX", "relevance_score": "0.375251", "ticker_sentiment_score": "0.2947", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/24/05/39027945/exclusive-coya-therapeutics-focused-on-neurodegenerative-diseases-has-gained-70-since-ipo-ceo-hig", "time_published": "20240527T134347", "authors": ["Vandana Singh"], "summary": "Coya Therapeutics Inc COYA is a clinical-stage biotechnology company developing treatments focused on regulatory T cells ( Tregs ) to target systemic inflammation and neuroinflammation. Since its IPO in December 2022, Coya shares have surged around 70%, significantly outperforming the Invesco ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/27/coya-ai.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.171646, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IVZ", "relevance_score": "0.040969", "ticker_sentiment_score": "0.303608", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.08183", "ticker_sentiment_score": "0.085151", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.588876", "ticker_sentiment_score": "0.22026", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/24/02/36937476/coya-therapeutics-secures-key-financing-in-its-fight-against-myriad-diseases", "time_published": "20240205T173723", "authors": ["Johnny Rice"], "summary": "Dr. Howard Burman, Ph.D, CEO of Coya Therapeutics Inc COYA, were guests on Benzinga's All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/screen_shot_2024-02-05_at_12.32.35_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.189954, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.576289", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/24/02/36936371/coya-therapeutics-secures-key-financing-in-its-fight-against-myriad-diseases", "time_published": "20240205T164016", "authors": ["Johnny Rice"], "summary": "Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc COYA, were guests on Benzinga's All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/02/05/screenshot_2024-02-05_at_11.39.34_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.183017, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.552443", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dr. Reddy's  ( RDY ) , COYA Ink Deal to Develop COYA 302 for ALS", "url": "https://www.zacks.com/stock/news/2194626/dr-reddys-rdy-coya-ink-deal-to-develop-coya-302-for-als", "time_published": "20231207T125700", "authors": ["Zacks Equity Research"], "summary": "Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.116864, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AGEN", "relevance_score": "0.363009", "ticker_sentiment_score": "0.023214", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.775055", "ticker_sentiment_score": "0.338696", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PBYI", "relevance_score": "0.21258", "ticker_sentiment_score": "0.131373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks to Watch: Adani Wilmar, Delta Corp, Paytm, Bharti Airtel, IRCON, BEL", "url": "https://www.business-standard.com/markets/news/stocks-to-watch-adani-wilmar-delta-corp-paytm-bharti-airtel-ircon-bel-123120700091_1.html", "time_published": "20231207T015939", "authors": ["Harshita Singh"], "summary": "Meanwhile, a sharp 3.8 per cent dip in Brent crude to $74 per barrel will provide support as both indices eye breaching 70,000 and 21,000, respectively. At 7:30 am, the Gift Nifty futures were nearly flat at 19,847 over Nifty futures' last close.", "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/07/full/1701912777-957.jpg?im=FeatureCrop,size=(826,465)", "source": "Business Standard", "category_within_source": "GoogleRSS", "source_domain": "www.business-standard.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.076633, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "FRBA", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.060785", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.142989", "ticker_sentiment_score": "0.065218", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dr Reddy's signs pact with Coya for investigational therapy of ALS", "url": "https://www.moneycontrol.com/news/business/markets/dr-reddys-sign-pact-with-coya-for-investigational-therapy-of-als-11864471.html", "time_published": "20231206T125025", "authors": [], "summary": "Dr. Reddy's will make a $7.5 million upfront payment to Coya. Under the terms of the agreement, Coya has granted Dr Reddy's an exclusive license to commercialise ...", "banner_image": "https://images.moneycontrol.com/static-mcnews/2018/09/2-battery-stocks-in-focus.jpg?impolicy=website&width=168&height=118", "source": "Money Control", "category_within_source": "Business", "source_domain": "www.moneycontrol.com", "topics": [], "overall_sentiment_score": 0.162999, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.687553", "ticker_sentiment_score": "0.346866", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Coya Therapeutics and Dr. Reddy's Laboratories enter into exclusive collaboration for investigational combination therapy to treat ALS", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/coya-therapeutics-and-dr-reddys-laboratories-enter-into-exclusive-collaboration-for-investigational-combination-therapy-to-treat-als/3329980/", "time_published": "20231206T124155", "authors": ["Health Desk"], "summary": "Dr. Reddy's Laboratories SA and Coya Therapeutics, Inc. on Wednesday announced that they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis ( ALS ) .", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/12/medicine-8287535_1280.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [], "overall_sentiment_score": 0.22473, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.719159", "ticker_sentiment_score": "0.355911", "ticker_sentiment_label": "Bullish"}]}, {"title": "Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight", "url": "https://www.prnewswire.com/news-releases/medical-second-opinion-global-market-to-register-stunning-growth-at-a-cagr-of-17-by-2028--delveinsight-301905294.html", "time_published": "20230821T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "The medical second opinion market is expanding rapidly due to the increasing frequency of malignancies, infectious diseases, genetic diseases, cardiovascular diseases, hematological diseases, orthopedic diseases, and other diseases around the world.", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.05963, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNPX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARM", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.048671", "ticker_sentiment_score": "-0.012897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVCTF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTHX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCPF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNBWY", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.048671", "ticker_sentiment_score": "0.037506", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGMF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGM", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELEV", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBRX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRYIF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.048671", "ticker_sentiment_score": "0.037506", "ticker_sentiment_label": "Neutral"}, {"ticker": "QEBR", "relevance_score": "0.07295", "ticker_sentiment_score": "-0.035688", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLOSF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMAC", "relevance_score": "0.024347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBIO", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.024347", "ticker_sentiment_score": "0.052734", "ticker_sentiment_label": "Neutral"}, {"ticker": "URGN", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.048671", "ticker_sentiment_score": "-0.031649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHA", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRVS", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKNA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AURA", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORYZF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.024347", "ticker_sentiment_score": "0.051825", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.024347", "ticker_sentiment_score": "-0.03954", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon", "url": "https://www.prnewswire.com/news-releases/dementia-market-to-grow-rapidly-estimates-delveinsight--key-companies-active-in-the-market---pfizer-eli-lilly-and-company-janssen-merck-biovie-biogen-vivoryon-sage-alnylam-bioxcel-eip-otsuka-alector-transposon-301885979.html", "time_published": "20230726T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.228916, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SNPX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.047607", "ticker_sentiment_score": "0.091165", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERE", "relevance_score": "0.047607", "ticker_sentiment_score": "0.083205", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.071357", "ticker_sentiment_score": "0.095722", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.047607", "ticker_sentiment_score": "0.083205", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXSM", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.023814", "ticker_sentiment_score": "0.071712", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAVA", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "PASG", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIVI", "relevance_score": "0.071357", "ticker_sentiment_score": "0.077488", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTAI", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.031839", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.023814", "ticker_sentiment_score": "0.038114", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVPI", "relevance_score": "0.023814", "ticker_sentiment_score": "0.086416", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHA", "relevance_score": "0.071357", "ticker_sentiment_score": "0.079506", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITCI", "relevance_score": "0.047607", "ticker_sentiment_score": "0.057191", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.047607", "ticker_sentiment_score": "0.049275", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.023814", "ticker_sentiment_score": "0.031839", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGTX", "relevance_score": "0.047607", "ticker_sentiment_score": "0.08317", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORYZF", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023814", "ticker_sentiment_score": "0.051649", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.071357", "ticker_sentiment_score": "0.077488", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33248741/coya-therapeutics-alzheimers-candidate-shows-lower-biomarker-levels-associated-with-neuroinflamma", "time_published": "20230717T142153", "authors": ["Vandana Singh"], "summary": "Coya Therapeutics Inc COYA reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 ( ld IL-2 ) in patients with Alzheimer's disease ( AD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/17/coya.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.20895, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.483434", "ticker_sentiment_score": "0.331196", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Immunotherapy Market Is Expected to Surpass $351.56 Billion By 2030 - Creative Medical Technology Holdings, Inc.  ( NASDAQ: CELZ )  Is Contributing to This Growth - Coya Therapeutics  ( NASDAQ:COYA ) , Creative Medical Tech  ( NASDAQ:CELZ ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33197087/the-immunotherapy-market-is-expected-to-surpass-351-56-billion-by-2030-creative-medical-technolog", "time_published": "20230712T122126", "authors": ["Faith Ashmore"], "summary": "Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/12/screenshot_2023-07-12_at_5.50.16_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.273354, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NHPEF", "relevance_score": "0.085936", "ticker_sentiment_score": "0.289581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COYA", "relevance_score": "0.170878", "ticker_sentiment_score": "0.125419", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.170878", "ticker_sentiment_score": "0.125419", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRT", "relevance_score": "0.170878", "ticker_sentiment_score": "0.125419", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELZ", "relevance_score": "0.48268", "ticker_sentiment_score": "0.356112", "ticker_sentiment_label": "Bullish"}]}, {"title": "COYA.O - | Stock Price & Latest News | Reuters", "url": "https://www.reuters.com/markets/companies/COYA.O", "time_published": "20230707T182800", "authors": [], "summary": "COYA.O - | Stock Price & Latest News ...", "banner_image": "", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [], "overall_sentiment_score": 0.035236, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.961451", "ticker_sentiment_score": "0.063765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday - Carrier Global  ( NYSE:CARR ) , Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/news/23/06/32776878/marsh-mclennan-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday", "time_published": "20230608T123133", "authors": ["Lisa Levin"], "summary": "Raymond James cut the price target for Brinker International, Inc. EAT from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close at $36.39 on Tuesday. Telsey Advisory Group lowered the price target for Oxford Industries, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/08/marsh__mclennan_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": -0.039043, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CARR", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.282039", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HCP", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.174674", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OXM", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.121757", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.498188", "ticker_sentiment_score": "-0.191442", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EPAM", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.271289", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CURV", "relevance_score": "0.262994", "ticker_sentiment_score": "0.006234", "ticker_sentiment_label": "Neutral"}, {"ticker": "EAT", "relevance_score": "0.262994", "ticker_sentiment_score": "0.006273", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.253775", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COYA", "relevance_score": "0.262994", "ticker_sentiment_score": "-0.050214", "ticker_sentiment_label": "Neutral"}, {"ticker": "FICO", "relevance_score": "0.262994", "ticker_sentiment_score": "0.281292", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OLLI", "relevance_score": "0.17715", "ticker_sentiment_score": "0.188169", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/06/32763482/blood-biomarker-brain-imaging-data-shows-coya-therapeutics-alzheimers-candidate-lowers-neuroinfla", "time_published": "20230607T180030", "authors": ["Vandana Singh"], "summary": "Coya Therapeutics Inc COYA reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for mild to moderate Alzheimer's Disease.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/07/coya.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.156257, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.931897", "ticker_sentiment_score": "0.371288", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket - AgriFORCE Growing Systems  ( NASDAQ:AGRI ) , ACM Research  ( NASDAQ:ACMR ) ", "url": "https://www.benzinga.com/news/23/06/32735888/why-bluejay-diagnostics-shares-are-trading-lower-by-12-here-are-20-stocks-moving-premarket", "time_published": "20230606T123613", "authors": ["Lisa Levin"], "summary": "Visionary Education Technology Holdings Group Inc. VEDU shares rose 85.8% to $0.7985 in pre-market trading. Chijet Motor Company, Inc. TTOO shares surged 51.3% to $0.1060 in pre-market trading after dipping around 31% on Monday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/06/bluejay_diagnostics_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.082754, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZURA", "relevance_score": "0.160633", "ticker_sentiment_score": "0.138917", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTLB", "relevance_score": "0.160633", "ticker_sentiment_score": "0.44554", "ticker_sentiment_label": "Bullish"}, {"ticker": "BJDX", "relevance_score": "0.238913", "ticker_sentiment_score": "-0.252617", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TTOO", "relevance_score": "0.160633", "ticker_sentiment_score": "0.084582", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLN", "relevance_score": "0.238913", "ticker_sentiment_score": "0.225879", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VEDU", "relevance_score": "0.160633", "ticker_sentiment_score": "0.259647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AYRO", "relevance_score": "0.238913", "ticker_sentiment_score": "-0.301692", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COYA", "relevance_score": "0.160633", "ticker_sentiment_score": "0.132162", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.238913", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIEW", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.11825", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSDI", "relevance_score": "0.080728", "ticker_sentiment_score": "0.220727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HTGM", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.24911", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KTTA", "relevance_score": "0.238913", "ticker_sentiment_score": "0.375451", "ticker_sentiment_label": "Bullish"}, {"ticker": "UK", "relevance_score": "0.160633", "ticker_sentiment_score": "0.169644", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SECO", "relevance_score": "0.160633", "ticker_sentiment_score": "0.082139", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACMR", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.35981", "ticker_sentiment_label": "Bearish"}, {"ticker": "BVS", "relevance_score": "0.160633", "ticker_sentiment_score": "-0.233274", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "TSLA, MANU, OMH, TGT, COYA: Top 5 Trending Stocks - Target  ( NYSE:TGT ) , Tesla  ( NASDAQ:TSLA ) , Manchester United  ( NYSE:MANU ) , Coya Therapeutics  ( NASDAQ:COYA ) , Ohmyhome  ( NASDAQ:OMH ) , Home Depot  ( NYSE:HD ) ", "url": "https://www.benzinga.com/markets/equities/23/05/32437759/tesla-manchester-united-ohmyhome-target-coya-why-these-5-stocks-are-drawing-investor-attention-t", "time_published": "20230517T013052", "authors": ["Bhavik Nair"], "summary": "U.S. markets ended in the red on Tuesday as a barrage of factors including the yet inconclusive debt ceiling limit talks between President Joe Biden and House Speaker Kevin McCarthy kept investors and traders in a cautious mode.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Jirapong_Manustrong_on_Shutterstock_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.151259, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MANU", "relevance_score": "0.34729", "ticker_sentiment_score": "0.358705", "ticker_sentiment_label": "Bullish"}, {"ticker": "TGT", "relevance_score": "0.34729", "ticker_sentiment_score": "0.133507", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.546745", "ticker_sentiment_score": "0.465119", "ticker_sentiment_label": "Bullish"}, {"ticker": "OMH", "relevance_score": "0.235823", "ticker_sentiment_score": "0.076164", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.34729", "ticker_sentiment_score": "0.367391", "ticker_sentiment_label": "Bullish"}, {"ticker": "HD", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.171886", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Coya Therapeutics  ( COYA )  Shares Are Shooting Higher Today - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32424087/why-coya-therapeutics-shares-are-shooting-higher-today", "time_published": "20230516T164201", "authors": ["Vandana Singh"], "summary": "Coya Therapeutics Inc COYA reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer's disease.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/coya.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.155438, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.970551", "ticker_sentiment_score": "0.297646", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why Momentum in Coya Therapeutics, Inc.  ( COYA )  Should Keep going", "url": "https://www.zacks.com/stock/news/2095686/heres-why-momentum-in-coya-therapeutics-inc-coya-should-keep-going", "time_published": "20230516T125005", "authors": ["Zacks Investment Research"], "summary": "If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is one of the several stocks that passed through our \"Recent Price Strength\" screen.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.395736, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.420316", "ticker_sentiment_score": "0.434243", "ticker_sentiment_label": "Bullish"}]}, {"title": "Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells  ( Tregs )  Be The Answer? - Eli Lilly  ( NYSE:LLY ) , Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/04/31785092/alzheimers-disease-largely-remains-a-mystery-with-a-lack-of-highly-effective-treatments-could-reg", "time_published": "20230413T115928", "authors": ["David Willey"], "summary": "In many ways, Alzheimer's disease ( AD ) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or reverse disease progression. What is clear is the urgency of developing proper treatments for ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/13/screenshot_2023-04-13_at_5.28.34_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.043263, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.1331", "ticker_sentiment_score": "0.045302", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.442522", "ticker_sentiment_score": "0.223206", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31527257/there-is-no-cure-for-als-but-coya-therapeutics-might-have-the-answer-according-to-a-new-clinical-", "time_published": "20230328T120342", "authors": ["David Willey"], "summary": "Coya Therapeutics COYA has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis ( ALS ) . The results for this novel biologic were positive, showing a slowing or even halting of ALS' progression.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/28/screenshot_2023-03-28_at_5.32.02_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.007284, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.57127", "ticker_sentiment_score": "0.08992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coya Therapeutics: This BioPharma Company Has Some Big News To Share - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31508476/coya-therapeutics-this-biopharma-company-has-some-big-news-to-share", "time_published": "20230327T120906", "authors": ["Johnny Rice"], "summary": "Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc COYA, was a guest on Benzinga's All Access. Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/27/screenshot_2023-03-27_at_5.10.17_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.155663, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.588876", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company - Why This Is a Major Moment For Drug Development - bluebird bio  ( NASDAQ:BLUE ) , Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31454405/coya-therapeutics-enters-first-of-its-kind-partnership-with-multi-billion-dollar-drug-company-why", "time_published": "20230322T120610", "authors": ["David Willey"], "summary": "Houston-based Coya Therapeutics COYA has entered into a partnership with Dr. Reddy's Laboratories Ltd. RDY, a world-leading pharmaceutical company based in India. Through this partnership, Coya will license Dr. Reddy's biosimilar product, Abatacept, allowing Coya to develop its combination ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/22/screenshot_2023-03-22_at_5.35.10_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.119281, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.598255", "ticker_sentiment_score": "0.100581", "ticker_sentiment_label": "Neutral"}]}, {"title": "COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar", "url": "https://www.zacks.com/stock/news/2068596/coya-dr-reddys-sign-deal-for-proposed-abatacept-biosimilar", "time_published": "20230321T152400", "authors": ["Zacks Investment Research"], "summary": "COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.123782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANVS", "relevance_score": "0.234307", "ticker_sentiment_score": "0.064555", "ticker_sentiment_label": "Neutral"}, {"ticker": "APTX", "relevance_score": "0.234307", "ticker_sentiment_score": "0.056153", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.725481", "ticker_sentiment_score": "0.238937", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31439521/coya-therapeutics-coya-302-treating-als-proves-effective-in-proof-of-concept-academic-clinical-st", "time_published": "20230321T135603", "authors": ["Kenneth Adams"], "summary": "Coya Therapeutics, Inc. COYA recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to significantly ameliorate disease progression ( stopping progression in all patients at 24 weeks with minimal decline ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/21/screenshot_2023-03-21_at_7.25.22_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.021527, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.644033", "ticker_sentiment_score": "-0.160231", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31439002/coya-therapeutics-reveals-proof-of-concept-data-from-small-study-with-als-patients", "time_published": "20230321T133854", "authors": ["Vandana Singh"], "summary": "Coya Therapeutics Inc COYA reported 48-week clinical data for its proof-of-concept open-label study in 4 Amyotrophic Lateral Sclerosis ( ALS ) patients indicating that treatment with COYA 302 appeared to ameliorate disease progression. During the 48-week treatment period, COYA 302 appeared to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/21/coya.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.110184, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.835692", "ticker_sentiment_score": "0.274751", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 - Dr Reddy's Laboratories  ( NYSE:RDY ) , Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/news/23/03/31420995/houston-based-coya-therapeutics-partners-with-multi-billion-dollar-global-drug-company-dr-reddys-lab", "time_published": "20230320T135433", "authors": ["Kenneth Adams"], "summary": "Coya Therapeutics, Inc. COYA recently announced a worldwide agreement with Dr. Reddy's Laboratories Limited. ( BSE: 500124 ) DRREDDY RDY DRREDDY, a global pharmaceutical company.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/20/screenshot_2023-03-20_at_7.23.50_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.226391, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.634626", "ticker_sentiment_score": "0.306029", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? - Eli Lilly  ( NYSE:LLY ) , Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/03/31191274/this-company-is-focused-on-treg-enhancing-therapies-could-this-be-medicines-next-frontier", "time_published": "20230303T131032", "authors": ["David Willey"], "summary": "Texas-based biotech company, Coya Therapeutics COYA, is positioning itself as a leader in a promising area of the medical field. When the father of company CEO and founder Howard Berman was diagnosed with dementia, Berman became inspired to turn his expertise in neuroscience towards developing a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/03/screenshot_2023-03-03_at_6.39.59_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.045661, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.108466", "ticker_sentiment_score": "0.054318", "ticker_sentiment_label": "Neutral"}, {"ticker": "COYA", "relevance_score": "0.266828", "ticker_sentiment_score": "0.032393", "ticker_sentiment_label": "Neutral"}]}, {"title": "Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas - Coya Therapeutics  ( NASDAQ:COYA ) ", "url": "https://www.benzinga.com/general/biotech/23/02/31069537/houston-based-coya-therapeutics-to-present-results-from-als-clinical-study-data-for-its-investiga", "time_published": "20230227T144902", "authors": ["Kenneth Adams"], "summary": "Coya Therapeutics, Inc. COYA recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis ( ALS ) with Coya's proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/27/shutterstock_728227891.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.117214, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COYA", "relevance_score": "0.202366", "ticker_sentiment_score": "-0.059147", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coya Therapeutics' Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments - Coya Therapeutics  ( NASDAQ:COYA ) , Exagen  ( NASDAQ:XGN ) ", "url": "https://www.benzinga.com/general/biotech/23/02/30925696/coya-therapeutics-expansion-of-exclusive-worldwide-licensing-agreement-with-arscience-biotherapeu", "time_published": "20230215T150413", "authors": ["Ernest Dela Aglanu"], "summary": "Houston, Texas-based Coya Therapeutics Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/15/screenshot_2023-02-15_at_8.33.06_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.203125, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "XGN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.218172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COYA", "relevance_score": "0.493128", "ticker_sentiment_score": "0.266583", "ticker_sentiment_label": "Somewhat-Bullish"}]}]}